Retatrutide vs Mounjaro: Which Weight Loss Medication to Choose in 2025-2026

Imagine you're standing in front of two doors. Behind one — a proven path that millions of people have already taken. Behind the other — a new route that promises to be even shorter. This is exactly how the choice between Mounjaro and Retatrutide (Retatrutide) looks today — two of the most promising weight loss products that are changing our understanding of weight correction.

And if you've already heard about tirzepatide, you might be wondering: should you wait for Retatrutide, or is it better to start the program right now? Let's figure it out together.

What is a dual and triple agonist — and why does it matter?

When we talk about modern weight correction products, the key word is receptors. These are like "locks" on the surface of cells that react to certain hormones. And this is where the main difference between Mounjaro and Retatrutide (Retatrutide) lies.

Mounjaro contains tirzepatide — a molecule that activates two receptor types simultaneously: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). This was already revolutionary, as previous products like Ozempic worked with only one receptor.

And now Retatrutide appears — a triple agonist that adds the glucagon receptor to this formula. This opens up an additional mechanism: glucagon stimulates fat breakdown in the liver and increases the body's energy expenditure.

What does this mean in practice? More mechanisms for controlling appetite, metabolism, and fat burning. But does this automatically mean better results? It's not that simple.

How Mounjaro works — and why it's already the gold standard

Mounjaro with active ingredient tirzepatide entered the market in 2022 and quickly became one of the most effective weight management products. Its uniqueness lies in dual action.

First mechanism — GLP-1. This hormone slows gastric emptying, so you feel full longer. It also affects hunger centers in the brain, reducing the desire to eat. Second mechanism — GIP. This hormone enhances insulin secretion in response to food and improves tissue insulin sensitivity.

According to SURMOUNT program clinical trials, participants on maximum tirzepatide dose lost an average of 22.5% of initial weight over 72 weeks. For a 100kg person, this means minus 22-23 kg — results previously only possible after bariatric surgery.

And here's an important point: Mounjaro is already available in Ukraine through the DOZA service. This is not a theoretical product of the future, but a real solution that works today.

The Mounjaro application program involves gradual dose escalation: from 2.5 mg to 15 mg. This allows the body to adapt and minimizes possible gastrointestinal reactions. Most DOZA clients note that already in the first month, appetite decreases significantly, and the feeling of satiety after eating becomes natural.

Retatrutide — what does the triple mechanism promise?

Retatrutide is the next evolutionary step. To the two familiar receptors (GLP-1 and GIP), it adds a third — the glucagon receptor. This third component makes it special.

Glucagon is a hormone opposite to insulin. While insulin lowers blood sugar and promotes fat storage, glucagon does the opposite: it stimulates glycogen breakdown in the liver and mobilizes fat stores for energy.

Preliminary study data shows Retatrutide participants demonstrated weight loss up to 24-26% over comparable periods. This is approximately 2-4% more than Mounjaro. Sounds impressive, but there are important caveats.

First, these results were obtained in controlled clinical trial conditions with carefully selected participants. Second, long-term safety data is still limited. Third, Retatrutide isn't yet approved by regulatory agencies — neither FDA nor EMA.

This means discussing its advantages over Mounjaro is premature. The scientific community needs more data.

Effectiveness comparison: the numbers speak for themselves

Let's look at specific indicators for both products. But remember: Mounjaro has significantly more evidence base, while Retatrutide data is based on smaller studies.

As you can see, Mounjaro has a key advantage: it's available here and now. You can start the weight loss program today, rather than waiting indefinitely for a new product to appear.

The price of Mounjaro reflects its unique value: it's an original Made in UK product with full DOZA specialist support. More details about program cost.

Who should choose Mounjaro — and who should wait?

This is the question we hear most often. And the answer, as always, depends on individual situation. But there are general guidelines.

Mounjaro is right for you if:

• You're ready to start weight management now, not wait years for new products
• Proven safety and effectiveness are important to you
• You want specialist support throughout the entire program
• You're looking for a solution that has already helped millions
• You have unwanted weight of 10kg or more

Consider waiting for Retatrutide if:

• You've already tried Mounjaro and it didn't give desired results (rare situation)
• You're not in a hurry with weight management
• You're prepared to wait 2-3 years for market availability

From our experience at DOZA, most clients achieve desired results precisely on Mounjaro. The potential additional 2-4% weight loss on Retatrutide is rarely a decisive factor compared to the ability to start now.

What happens to your body on each product: week by week

Let's examine how body adaptation typically proceeds. These stages are characteristic of both products, as they share GLP-1 and GIP mechanisms.

Week 1-2: beginning of changes

You make your first injection and, honestly, might not feel anything special. Some clients notice slight appetite reduction, others don't. This is normal. The body needs time.

Some people experience mild nausea or stomach discomfort. This signals that the product has started working. Usually these feelings pass within a few days.

Week 3-4: first results

Here's where it gets interesting. Most DOZA clients say: "I simply forgot to eat lunch." Appetite decreases not through willpower, but naturally. Portions become smaller, and you finally feel full after eating.

Weight starts dropping. Typically — 2 to 4kg in the first month on starting dose.

Month 2-3: adaptation and steady progress

Dose gradually increases. Effect becomes more pronounced. Many clients note changing eating habits: wanting lighter food, less sweets, less "eating from boredom."

Average weight loss — 5-8% of initial weight in first 3 months.

Regarding Retatrutide — due to additional glucagon component, there could theoretically be additional reactions related to increased blood sugar and liver stress. But this is still theory — specific data will emerge after clinical trial completion.

Important: under DOZA specialist supervision, any body reactions are minimized and managed. You're not left alone with the process.

Why "triple vs dual" comparison is oversimplification

Some internet articles present the situation as: three mechanisms are better than two, therefore Retatrutide is automatically more effective. But medicine doesn't work that way.

First, effectiveness depends not only on mechanism quantity, but on their balance and interaction. Tirzepatide in Mounjaro has optimally selected GLP-1 and GIP receptor activation ratio, tested through years of research.

Second, additional mechanism means additional complexity. Glucagon component may be useful for fat burning, but could also affect blood sugar unpredictably in some people.

Third, the 2-4% weight loss difference (if confirmed) may be statistically significant in studies but have little practical meaning for specific individuals. Especially if this difference costs indefinite waiting.

Real stories: how Mounjaro changes lives

Scientific data is important, but sometimes personal experience speaks louder.

More real stories and results — on the reviews page. These are not staged photos — these are real people who completed the DOZA program.

We see this in our clients constantly: people who postponed decisions for years regret lost time. Those who started — celebrate results.

Mounjaro vs Ozempic: where does Retatrutide fit in this lineup?

For complete picture, it's worth mentioning another popular product — Ozempic with active ingredient semaglutide.

Ozempic is a single agonist working only with GLP-1 receptors. It's effective but inferior to Mounjaro in weight loss indicators. Average difference — about 5-7% in Mounjaro's favor.

Detailed comparison of Mounjaro and Ozempic will help understand the differences.

Retatrutide in this lineup is the next evolutionary step. But evolution doesn't mean previous solutions became ineffective. Mounjaro remains the gold standard among available products.

How to choose: practical decision algorithm

Let's summarize everything in a simple algorithm.

Step 1: Determine urgency

Do you have medical reasons for weight loss (type 2 diabetes, joint problems, cardiovascular risks)? If yes — delay is dangerous. Mounjaro is your choice.

Step 2: Assess availability

Mounjaro is available in Ukraine through DOZA. Catalog with current prices. Retatrutide is not. Unknown when it will be.

Step 3: Analyze expectations

If you need to lose 15-25% weight — Mounjaro provides this. Potential additional 2-4% on Retatrutide is a bonus, but not reason to wait years.

Step 4: Consult specialist

Browse Retatrutide catalog or Mounjaro catalog — DOZA specialist will help choose the optimal option.

Individual situation is always unique. Free DOZA consultation will help figure out which approach is optimal for you.

Where to order DOZA products

DOZA supplies all products mentioned in the article with official cold chain and 24/7 specialist support. Choose what you need:

• Buy Ozempic in Ukraine — original semaglutide from Novo Nordisk with thermal delivery. Current Ozempic prices 2026 — from ₴1,600 for starting dose.

Where to buy

DOZA supplies the products mentioned in this article with an official cold chain and 24/7 specialist support:

• Buy Retatrutide in Ukraine — next-generation triple agonist (GLP-1 + GIP + glucagon), ALLUVI and SYNEDICA pens with cold-chain delivery.